AzTrials
AzTrials

Leishmaniasis, VisceralNCT06793111

Visceral Leishmaniasis in Emilia-Romagna (Leishmania-2019)

An observational study of Leishmaniasis, Visceral, run by IRCCS Azienda Ospedaliero-Universitaria di Bologna at 5 sites in Italy.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

According to reports in the literature, from 2012 to date, there has been an increase in the number of diagnosed cases of autochthonous visceral Leishmania in the Province of Bologna. Read more about this study

Who is it for?
Ages 6 to 90 years
Conditions the study is for
Leishmaniasis, Visceral
How many people
300 participants
Where
5 sitesItaly
Study dates
21 Apr 2020to 31 Dec 2025
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 6 to 90 years
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: Any patient with a diagnosis of established Visceral Leishmaniasis but also patients with a diagnosis of prior Visceral Leishmaniasis.

Who may be able to join

  • Patients of any age with microbiologically established diagnosis of LV.
  • Obtaining Informed Consent.

Who cannot join

  • not having obtained Informed Consent

Trial locations and contacts

5 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Pierluigi Viale, MD contact

+390512143353

pierluigi.viale@unibo.it

Silvia Cretella, BSc; MBio contact

+390512143353

silvia.cretella@aosp.bo.it

5 sites in 1 country

Italy5 sites, 5 recruiting
  • IRCCS Azienda Ospedaliero-Universitaria di Bologna

    Bologna, 40138

    Pierluigi Viale, MD, +390512143353, pierluigi.viale@unibo.it

    Silvia Cretella, BSc; MBiol, +390512143353, silvia.cretella@aosp.bo.it

    Recruiting
  • Ospedale M. Bufalini di Cesena, AUSL della Romagna

    Cesena, Forlì-Cesena, 47521

    Francesco Cristini, MD, +390547352705, francesco.cristini@auslromagna.it

    Recruiting
  • Ospedale G.B. Morgagni L. Pierantoni di Forlì

    Forlì, Forlì-Cesena, 47121

    Francesco Cristini, MD, +390543735894; +390543735839, francesco.cristini@auslromagna.it

    Recruiting
  • Ospedale S. Maria delle Croci di Ravenna, AUSL della Romagna

    Ravenna, 48121

    Elisa Vanino, MD, +390544285111, elisa.vanino@auslromagna.it

    Recruiting
  • Ospedale Infermi di Rimini, AUSL della Romagna

    Rimini, 47923

    Carlo Biagetti, MD, +390541705506 ; +390541705315, carlo.biagetti@auslromagna.it

    Romina Gianfreda, MD

    Recruiting

Other trials in Italy

About this study

Official title: Visceral Leishmaniasis in Emilia-Romagna

According to reports in the literature, from 2012 to date, there has been an increase in the number of diagnosed cases of autochthonous visceral Leishmania in the Province of Bologna.

In this context, it was decided to carry out a retrospective prospective observational study, which is essential to describe the epidemiology of LV in order to outline the scientific and rational bases necessary for the drafting of guidelines to standardise the diagnostic and therapeutic approach to this disease, in order to reduce the diagnostic delay and improve therapeutic results.

therapeutic outcome. In addition, epidemiological data will make it possible to identify possible new strategies to control the disease, which are essential for reducing its transmission.

Read the detailed description

The term leishmaniasis refers to a heterogeneous group of anthropo-zoonoses caused by protozoa obligate intracellular protozoa, parasites of humans and various wild and domestic animals, belonging to the genus Leishmania. Despite being the cause of recurrent epidemic outbreaks with high rates of morbidity and mortality rates in certain geographical areas, the World Health Organisation (WHO) includes them among the Neglected Tropical Diseases. About 350 million people live in areas at risk for leishmaniasis with an estimated global prevalence of 12 million. The annual global incidence is estimated to be between 0.2 and 0.4 million cases for Visceral Leishmaniasis (LV) and between 0.7 and 1.2 million cases for Cutaneous Leishmaniasis Cutaneous. Leishmaniases are endemic infections in tropical, subtropical and temperate zones of all continents except Australia and Antarctica. More than 90% of LV cases are diagnosed in six countries: Bangladesh, Brazil, Ethiopia, India, South Sudan and Sudan, while the majority of LC cases are diagnosed in Afghanistan, Algeria, Brazil, Colombia, Iran, Pakistan, Peru, Saudi Arabia and Syria.

Leishmaniasis is also endemic in the Mediterranean Basin, including Italy, and in this area about 5% of global cases are found there, with a clear prevalence of visceral forms.

The incubation period varies from 4 to 10 months, but cases have been described in which incubation lasted for several years.

The onset is mostly gradual and insidious and the most characteristic clinical manifestations are asthenia fever (often initially framed as FUO), night sweats, anorexia and weight loss, splenomegaly, hepatomegaly and lymphadenomegaly. From a laboratory point of view, characteristic are anaemia, leucopenia and thrombocytopenia, more or less associated with each other, up to full-blown pancytopenia.

Dysprotidemia with hypergammaglobulinemia and hypoalbuminemia is typical. If not adequately treated, visceral leishmaniasis evolves towards a condition of cachexia and profound general decay and may prove fatal. A rare and serious complication of LV is the haemophagocytic syndrome. According to the 2010 WHO Leishmaniasis Control Report, a confirmed case of LV is defined as the association between typical clinical signs and symptoms (fever, splenomegaly, weight loss, etc.) and positivity of a parasitological examination (microscopy, RT-PCR or culture) in the presence or absence of positivity of serological investigations.

The methods available for the diagnosis of LV include:

  • Serological tests: detection of Leishmania-specific IgG (or total Ig) in plasma or serum. enzyme immunoassay (EIA), indirect immunofluorescence assay (IFAT), immunochromatographic test (ICT) based on the immunochromatographic test (ICT) based on rK39 antigen, Western blot (WB). Disadvantages: these tests remain positive over time (it is not always possible to distinguish relapses); they may be positive in individuals with asymptomatic infection; they may be falsely negative in immunodepressed individuals (20-60% of cases).
  • Molecular biology tests: detection of Leishmania DNA by RT-PCR on peripheral blood bone marrow blood or any other material. Molecular tests are now considered the most sensitive methods sensitive for the diagnosis of LV and the accuracy in identifying Leishmania DNA is high for bone marrow aspirate and peripheral blood samples. RT-PCR should be performed in case the presence of suspicious symptoms and serological test positivity. However, in the presence of strong suspicion clinical suspicion or in immunocompromised patients, RT-PCR should also be performed in case of a negative serology test.

Quantitative RT-PCR on peripheral blood may be useful in patients immunocompromised patients for monitoring parasitukaemia during therapy.

Direct microscopic examination on bone marrow blood smear: sensitivity is variable (25-85%) and lower than the sensitivity of molecular methods.

  • Culture examination: culture isolation from bone marrow blood takes a long time (at least 4 weeks). Culture allows the isolation of the strain of Leishmania responsible for the disease and can also be can also be performed from biopsy tissue.

According to reports in the literature, from 2012 to date, there has been an increase in the number of diagnosed cases of autochthonous visceral Leishmania in the Province of Bologna.

In this context, it was decided to carry out a retrospective prospective observational study, which is essential to describe the epidemiology of LV in order to outline the scientific and rational bases necessary for the drafting of guidelines to standardise the diagnostic and therapeutic approach to this disease, in order to reduce the diagnostic delay and improve therapeutic results.

therapeutic outcome. In addition, epidemiological data will make it possible to identify possible new strategies to control the disease, which are essential for reducing its transmission.

Keywords
Leishmaniasis
Medical subject headings
Leishmaniasis, Visceral, Leishmaniasis

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Epidemiology of Visceral Leishmaniasis (VL) cases in Emilia-Romagna

    In-depth description of the epidemiology of autochthonous visceral Leishmaniasis in the Emilia-Romagna region, focusing on the increase in diagnosed cases since 2012. The study will provide critical data for identifying trends in incidence, affected populations, and geographical hotspots, essential for guiding public health interventions.

    Measure: Number of diagnosed cases per year across participating centers. Unit of measure: Number of cases (n). Collection method: Review of medical records and epidemiological registries.

    Measured: March 2020 - February 2025

  2. Socio-demographic and clinical characteristics of patients diagnosed with VL

    Detailed analysis of the clinical features and presentations of diagnosed LV cases, including common symptoms such as fever, weight loss, splenomegaly, and laboratory findings like anemia and pancytopenia. This analysis will help establish a clearer clinical profile for early diagnosis and treatment strategies.

    Measure: Age, gender, comorbidities, geographic area of residence, known exposure mode.

    Unit of measure: Mean ± standard deviation (continuous variables), percentages (categorical variables).

    Collection method: clinical data collection.

    Measured: March 2020 - February 2025

Secondary outcomes (3)
  1. Diagnostic accuracy of methods used for VL identification

    Evaluation of the diagnostic accuracy of available methods (serological tests, RT-PCR, direct microscopy, and culture) in identifying LV cases, particularly in immunocompromised patients and those with atypical presentations. The study will assess the effectiveness of these tests in different clinical scenarios, including their sensitivity and specificity.

    Measure: Sensitivity, specificity, positive and negative predictive values of diagnostic tests (EIA, IFAT, RT-PCR, rK39 ICT, direct microscopy).

    Unit of measure: Percentage (%). Collection method: Comparison with the diagnostic gold standard (bone marrow biopsy with parasite identification).

    Measured: March 2020 - February 2025

  2. Monitoring of therapy tolerability

    Ongoing assessment of the safety and tolerability of therapeutic interventions used to treat LV, with a focus on identifying potential adverse effects or complications arising from current treatment regimens. This includes monitoring for any therapy-related side effects and evaluating the suitability of treatment options in different patient populations.

    Measure: Number of participants with adverse events (evaluated according to CTCAE v4.0 criteria).

    Unit of measure: Number of adverse events (n), percentage (%). Collection method: Adverse event reporting forms and clinical reports.

    Measured: March 2020 - February 2025

  3. Evaluation of therapeutic outcomes of treated cases.

    Comprehensive assessment of the therapeutic outcomes in patients treated for LV, measuring the effectiveness of current treatment protocols in terms of clinical improvement, survival rates, and relapse prevention. This will also involve tracking long-term patient recovery and any subsequent need for retreatment.

    Measure: Complete cure rate, recurrence rate at 6 and 12 months, disease-related mortality.

    Unit of measure: Percentage (%), time to recurrence in days (d). Collection method: Clinical and laboratory follow-up.

    Measured: March 2020 - February 2025

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Jan 2025
  2. Study start21 Apr 2020
  3. Primary completion31 May 2025 (estimated)
  4. Study completion31 Dec 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Other
Enrolment
300 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06793111
Sponsor's protocol ID
Leishmania-2019
Status last verified
Dec 2024
First submitted
30 Dec 2024
Last updated
27 Jan 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Leishmaniasis, Visceral, run by IRCCS Azienda Ospedaliero-Universitaria di Bologna at 5 sites in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 27 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 5 sites in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Pierluigi Viale, MD (+390512143353, pierluigi.viale@unibo.it), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Epidemiology of Visceral Leishmaniasis (VL) cases in Emilia-Romagna (time frame: March 2020 - February 2025). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Jan 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in